ITM announces FDA acceptance of New Drug Application (NDA) and PDUFA Date for n.c.a. 177Lu-edotreotide...

Avenzo Therapeutics granted Fast Track Designation for AVZO-1418, a potential best-in-class EGFR/HER3 bispecific antibody-drug conjugate,...

Arrivent Biopharma received FDA IND clearance for ARR-217, a CDH-17 targeted ADC

Celltrion’s solid tumor ADC drug candidate CT-P73 has received approval for phase 1 clinical trials...

BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, demonstrates a median overall survival (OS) of 21.5...

Day One to acquire Mersana Therapeutics to advance mission to bring new medicines to people...